Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma

Soluble AXL as a marker of disease progression and survival in melanoma

(2020) Karine Flem-Karlsen et al.   PLoS One

AXL as a Target in Breast Cancer Therapy

(2020) Sierra A. Colavito   Journal of Oncology

AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer

(2020) Nellie K McDaniel et al.   CLINICAL CANCER RESEARCH

Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities

(2020) Yusha Sun et al.   JOURNAL OF NEURO-ONCOLOGY

Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment

(2020) Mai Tanaka et al.   Cancers

AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer

(2020) Claudia Cardone et al.   EUROPEAN JOURNAL OF CANCER

Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature

(2019) Salvatore Grisanti et al.   Journal of Neurosurgical Sciences

Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics

(2018) Elisa Holstein et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

(2018) Giuseppe Lombardi et al.   LANCET ONCOLOGY

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

(2017) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

EGFR heterogeneity and implications for therapeutic intervention in glioblastoma

(2017) Eskil Eskilsson et al.   NEURO-ONCOLOGY

Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival

(2017) Julia Onken et al.   Oncotarget

Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy

(2016) M. Scaltriti et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer

(2016) Miles A. Miller et al.   CLINICAL CANCER RESEARCH

The impact of hypoxia and its modification of the outcome of radiotherapy

(2016) Michael R. Horsman et al.   JOURNAL OF RADIATION RESEARCH

MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation

(2016) Bishuang Cai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reprogramming the immunological microenvironment through radiation and targeting Axl

(2016) Todd A. Aguilera et al.   Nature Communications

Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance

(2016) M. A. Miller et al.   Cancer Discovery

Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo

(2016) Julia Onken et al.   Oncotarget

AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective

(2015) Samuel H. Myers et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

(2015) L Zhou et al.   ONCOGENE

Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells

(2015) Chun-Yu Cho et al.   RNA

Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells

(2015) Mikaella Vouri et al.   Oncotarget

Radiation promotes malignant progression of glioma cells through HIF-1alpha stabilization

(2014) Young-Heon Kim et al.   CANCER LETTERS

The Role of Factor Inhibiting HIF (FIH-1) in Inhibiting HIF-1 Transcriptional Activity in Glioblastoma Multiforme

(2014) Enfeng Wang et al.   PLoS One

The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells

(2013) A. S. Meyer et al.   Science Signaling

ABL Regulation by AXL Promotes Cisplatin Resistance in Esophageal Cancer

(2012) J. Hong et al.   CANCER RESEARCH

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

Axl-dependent signalling: a clinical update

(2011) Vyacheslav A. Korshunov   CLINICAL SCIENCE

Proteolytic Cleavage of Notch: “HIT and RUN”

(2011) G. van Tetering et al.   CURRENT MOLECULAR MEDICINE

Caffeine Confers Radiosensitization of PTEN-Deficient Malignant Glioma Cells by Enhancing Ionizing Radiation-Induced G1 Arrest and Negatively Regulating Akt Phosphorylation

(2010) B. Sinn et al.   MOLECULAR CANCER THERAPEUTICS

Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells

(2009) Zhizhong Li et al.   CANCER CELL

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Axl and Growth Arrest Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme

(2008) M. Hutterer et al.   CLINICAL CANCER RESEARCH